Physician profile
Eda W Lam
NPI 1043476146
$5,132.29
in general payments reported to CMS, 2019-2025
21 companies · $1,103 in 2025
The $1,103 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $68.11 · 2021: $446 · 2022: $1,069 · 2023: $1,505 · 2024: $445 · 2025: $1,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,950 · Entertainment: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,949.81 |
| Entertainment | $103.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,174.99 | 2019-2025 | Cequa |
| Alcon Vision LLC | $779.77 | 2020-2025 | Tryptyr, Rocklatan, Rhopressa |
| Bausch & Lomb Americas INC. | $579.78 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Novartis Pharmaceuticals Corporation | $568.53 | 2019-2023 | |
| Oyster Point Pharma, INC. | $332.67 | 2022-2025 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $252.99 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $242.07 | 2024-2025 | Xdemvy |
| Coopervision INC. | $207.00 | 2019-2025 | Clariti Contact Lens |
| Dompe US, INC. | $182.38 | 2021-2025 | Oxervate |
| Abbvie INC. | $127.85 | 2022-2024 | |
| Horizon Therapeutics Plc | $124.48 | 2023 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $119.16 | 2019 | |
| Optos, INC. | $103.31 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Glaukos Corporation | $99.00 | 2021 | |
| Allergan, INC. | $80.99 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $37.37 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Biotissue Holdings INC. | $31.78 | 2019-2021 | |
| Maculogix, INC. | $30.97 | 2021 | |
| Thea Pharma INC. | $19.88 | 2023 | |
| Omeros Corporation | $18.96 | 2021 | |
| Ivantis, INC | $18.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eda Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.